Key TakeawaysModerna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory syncytial virus (RSV) vaccine.The biotech reported it was advised by regulators that their review wouldn't be completed until the end of the month, whereas previously it was expected on May 12.Moderna is moving to produce vaccines for other diseases now that demand for its COVID-19 shot has declined with the pandemic over. Moderna (MRNA) shares lost ground in intraday trading Friday as the ...

Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end of May due to "administrative constraints" at the agency.The FDA was expected to make a decision on the RSV shot on Sunday. The agency has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said in a release.Investors are watching the upcoming approval closely as Moderna tries to re ...

The COVID-19 pandemic thrust this company's science -- and its stock -- into the spotlight.Five years ago, pharmaceutical company Moderna (MRNA 0.68%) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking to make such a bet.Then the COVID-19 pandemic materialized. As it turns out, the coronavirus was the ideal target for ...

Moderna (MRNA) stock broke out for the first time in over a year on May 2 after the biotech company notched a big quarterly beat on the back of its Covid vaccine.X During the quarter, the Covid vaccine called Spikevax brought in $167 million in sales, well above forecasts for $93 million, according to FactSet. Losses also came in better than expected at $3.07 per share, though reversed from a year-earlier gain.Notably, Moderna kept its outlook for the year.Later this month, the Food and Drug Administration ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) (IRS Employer Identification No.) 325 Binney Street Cambridge, Massachusetts 02142 (Address of Principal Executive Offices) (Zip Code) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdiction of ...

Moderna, Inc. (MRNA) reported earnings of $3.07 per share in the first quarter of 2024, beating the Zacks Consensus Estimate of a loss of $3.59. In the year-ago period, management posted earnings of 19 cents per share. This bottom-line downtick was due to lower product sales during the quarter.Revenues in the quarter were $167 million, beating the Zacks Consensus Estimate of $124.7 million. Total revenues declined 91% year over year due to reduced COVID-19 vaccine sales during the quarter.Shares of Moderna ...

Forward-looking statements and disclaimer 2 Financials Jamey Mock, CFO usiness Revie | --- | --- | --- | --- | --- | --- | |--------------------------|-------|-------|-------|-------|-------| | | | | | | | | vaccines | | | | | | | addressing | | | | | | | respiratory and | | | | | | | latent + other pathogens | | | | | | | | | | | | | © 2024 Moderna, Inc. All rights reserved. Financial figures in this presentation as of, and for the quarterly periods ended, March 31, 2024, and March 31, 2023, are unaudited. ...

The biotech sector includes companies that utilize biological processes to develop technologies and products for a wide range of industries. This includes healthcare, agriculture, and environmental management. These companies often focus on innovative therapies, medical diagnostics, and genetic research. Biotech stocks are known for their high growth potential. This is primarily due to the revolutionary nature of their products and the increasing demand for advanced medical treatments.Investing in biotech s ...

Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.48%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.78 per share when it actually produced earnings of $0.55, delivering a surprise of 170.51%.Over the last four quarters, the company ...

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Moderna beats loss estimates, revenue expectationsCopy link to sectionIn the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.07 per share, which was less than the anticipated loss of ...